Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.57 |
| ▸ | CTSL | P07711 | 5/20 | 0.44 |
| ▸ | CTSB | P07858 | 5/20 | 0.44 |
| ▸ | CTSH | P09668 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14876797 | 0.99 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL8387889 | 0.89 | CTSK (0.57) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL8695376 | 0.89 | CTSK (0.57) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL8972183 | 0.89 | CTSK (0.57) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL1783728 | 0.87 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL231491 | 0.87 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL4292353 | 0.87 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL20756961 | 0.87 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL18328801 | 0.87 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL258985 | 0.87 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337269-B1 | ASSOCIATION OF CALPAIN INHIBITORS AND REACTIVE OXYGEN SPECIES TRAPPING AGENTS | SOD CONSEILS RECH APPLIC (FR) | 2006-11-08 | — | — | EP | claimed |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | NYSNOBIO IRELAND DAC (IE) | 2020-03-19 | — | — | US | disclosed |
| US-10155936-B2 | Parkin ligase activation methods and compositions | An2H Discovery Limited (IE) | 2018-12-18 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155936-B2 | Parkin ligase activation methods and compositions | PINK1, XIAP, STUB1 | CTSK 1623/4885CTSL 2894/4885CTSB 665/4885 |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | CTSK 1623/4885CTSL 2894/4885CTSB 665/4885 |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | CTSK 1623/4885CTSL 2894/4885CTSB 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.